The estimated Net Worth of Richard J Kim is at least $2.63 Million dollars as of 2 October 2017. Mr. Kim owns over 48 units of Intercept Pharmaceuticals Inc stock worth over $212,895 and over the last 7 years he sold ICPT stock worth over $20,322. In addition, he makes $2,399,330 as President and U.S. Commercial & Strategic Marketing at Intercept Pharmaceuticals Inc.
Richard has made over 3 trades of the Intercept Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 48 units of ICPT stock worth $2,789 on 2 October 2017.
The largest trade he's ever made was selling 89 units of Intercept Pharmaceuticals Inc stock on 14 July 2017 worth over $11,449. On average, Richard trades about 8 units every 4 days since 2017. As of 2 October 2017 he still owns at least 11,205 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kim stock trades at the bottom of the page.
Richard Kim serves as President, U.S. Commercial & Strategic Marketing of the Company. He has over 20 years of commercial, marketing and managerial experience in the biopharmaceutical industry in the United States and abroad. Prior to joining the Company, Mr. Kim worked at Bristol-Myers Squibb starting in 2004, where he most recently served as General Manager, Hepatitis C Worldwide Commercialization. Prior to that, Mr. Kim held a number of roles of increasing responsibility at Bristol-Myers Squibb, including Vice President, SPRYCEL Brand Lead, Oncology Global Marketing; Vice President, U.S. In-Line Oncology and Global Marketing for Necitumumab; and Vice President, East Area Sales, Cardiovascular and Metabolics. Prior to holding these positions, Mr. Kim held a range of senior positions in the United States, Canada and Australia at Schering-Plough, which was acquired by Merck & Co., Inc. Mr. Kim earned his bachelor’s degree in chemistry from the University of Alberta.
As the President and U.S. Commercial & Strategic Marketing of Intercept Pharmaceuticals Inc, the total compensation of Richard Kim at Intercept Pharmaceuticals Inc is $2,399,330. There are 3 executives at Intercept Pharmaceuticals Inc getting paid more, with Mark Pruzanski having the highest compensation of $6,615,780.
Richard Kim is 51, he's been the President and U.S. Commercial & Strategic Marketing of Intercept Pharmaceuticals Inc since 2019. There are 16 older and 5 younger executives at Intercept Pharmaceuticals Inc. The oldest executive at Intercept Pharmaceuticals Inc is Keith Gottesdiener, 66, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, and Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: